Research Analysts Issue Forecasts for Ocugen Q3 Earnings

Ocugen, Inc. (NASDAQ:OCGN) – Equities researchers at HC Wainwright cut their Q3 2026 EPS estimates for Ocugen in a report released on Friday, August 7th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.07) per share for the quarter, down from their prior estimate of ($0.06). The consensus estimate for Ocugen’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Ocugen’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.28) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.09) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.36) EPS, FY2028 earnings at ($0.41) EPS, FY2029 earnings at $0.14 EPS and FY2030 earnings at $1.08 EPS.

Other analysts have also recently issued research reports about the company. Wall Street Zen cut Ocugen from a “hold” rating to a “sell” rating in a report on Saturday. Canaccord Genuity Group cut their price target on Ocugen from $12.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Finally, Weiss Ratings downgraded shares of Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

Ocugen Trading Up 2.3%

Shares of OCGN opened at $1.31 on Tuesday. The stock has a fifty day moving average price of $1.34 and a two-hundred day moving average price of $1.56. The company has a debt-to-equity ratio of 4.17, a quick ratio of 0.80 and a current ratio of 0.80. Ocugen has a 52-week low of $0.96 and a 52-week high of $2.73. The company has a market cap of $444.23 million, a price-to-earnings ratio of -5.04 and a beta of 2.21.

Ocugen (NASDAQ:OCGN) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The company had revenue of $1.49 million during the quarter, compared to analyst estimates of $0.89 million.

Institutional Trading of Ocugen

Hedge funds have recently added to or reduced their stakes in the business. Cora Capital Advisors LLC grew its stake in Ocugen by 27.5% in the fourth quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock valued at $41,000 after acquiring an additional 6,500 shares during the period. Jain Global LLC lifted its holdings in shares of Ocugen by 7.2% during the 4th quarter. Jain Global LLC now owns 114,690 shares of the company’s stock valued at $155,000 after purchasing an additional 7,686 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Ocugen by 56.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock valued at $36,000 after purchasing an additional 13,326 shares in the last quarter. CTC Alternative Strategies Ltd. acquired a new position in shares of Ocugen in the 1st quarter valued at approximately $34,000. Finally, Diversify Advisory Services LLC bought a new stake in Ocugen during the 2nd quarter worth approximately $25,000. Institutional investors and hedge funds own 10.27% of the company’s stock.

Insider Buying and Selling

In other news, CFO Treerita Essali Johnson-Greene bought 21,000 shares of the business’s stock in a transaction on Monday, June 15th. The shares were bought at an average cost of $1.23 per share, for a total transaction of $25,830.00. Following the completion of the acquisition, the chief financial officer owned 521,000 shares in the company, valued at approximately $640,830. This trade represents a 4.20% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.95% of the company’s stock.

Trending Headlines about Ocugen

Here are the key news stories impacting Ocugen this week:

• Negative Sentiment: HC Wainwright cut its estimates across several periods. The firm lowered its FY2026 EPS forecast to a loss of $0.28 from $0.25, FY2027 to a loss of $0.36 from $0.26, and FY2028 to a loss of $0.41 from a prior estimate of $0.05. Quarterly estimates for Q3 2026 through Q4 2027 were also reduced, pointing to a longer period of expected operating losses. Ocugen analyst estimate report
• Negative Sentiment: Long-term earnings expectations were sharply downgraded. HC Wainwright reduced its FY2029 EPS forecast to $0.14 from $0.61 and FY2030 to $1.08 from $1.56. Although the estimates still imply a potential return to profitability, the much lower projections weaken the longer-term earnings outlook.
• Negative Sentiment: Noble Financial also lowered its forecasts. Noble cut its FY2026 EPS estimate to a loss of $0.26 from $0.22 and reduced Q3 2026 EPS to a loss of $0.06 from $0.05 and Q4 2026 to a loss of $0.07 from $0.06. These revisions reinforce concerns about near-term cash consumption and execution.
• Neutral Sentiment: The broader earnings picture remains speculative. Ocugen is expected to remain unprofitable in the near term, while the available estimates project profitability beginning in FY2029. With OCGN trading near its 50-day average and well below its one-year high, investor focus is likely to remain on clinical progress, funding needs and the company’s ability to convert its pipeline into revenue.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.